
This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of zzso Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess zzso and that the majority of them allow the maintenance of the reduced zzso for at least 1 zzso However, the loss of zzso attributable to these drugs is in general rather modest, approaching only zzso zzso per week during the first 6 months of treatment, and at least a partial regain of zzso occurs when these drugs are used for periods longer than 1 zzso All of these drugs induce several adverse zzso Although most of these adverse effects are mild and zzso the prolonged use of zzso or zzso zzso drugs, or their use as combination treatment, may induce serious and potentially life-threatening zzso such as primary pulmonary hypertension or zzso heart zzso The zzso zzso drugs are not recommended for the treatment of zzso since their safety has never been evaluated in long term clinical trials, and because of their zzso effects on the cardiovascular and nervous zzso The zzso drugs, such as zzso and zzso have been the most widely used during the past zzso however, both these compounds have recently been withdrawn from the market, since their use was associated with serious cardiovascular zzso The safety of the prolonged therapeutic use of newer compounds such as zzso and zzso has not yet been zzso zzso none of the currently available zzso medications meets the criteria of an zzso zzso zzso and, if zzso these medications should be used with caution and only under careful medical zzso Since obesity is zzso as a chronic zzso condition, and since classical zzso therapeutic approaches lack long term zzso there is clearly a need for an efficient pharmacological treatment offering an acceptable safety zzso Such a treatment is not available at zzso Development of new agents and a more careful assessment of the safety of currently available drugs are zzso 

